Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin plus Pembrolizumab Maintenance in NSCLC
NCT05705466Phase 2Withdrawn
- Sponsor
- Kartos Therapeutics
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Navtemadlin + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoints: Recommended Phase 2 Dose at 21 days and Progression-Free Survival at 64 months. Planned start Jun 2023; status: withdrawn.
02
Drugs
navtemadlin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05705466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705466.